Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 27;30(4):339-358.
doi: 10.1515/revneuro-2016-0035.

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Affiliations
Review

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Jason Gandhi et al. Rev Neurosci. .

Abstract

Protein folding is a complex, multisystem process characterized by heavy molecular and cellular footprints. Chaperone machinery enables proper protein folding and stable conformation. Other pathways concomitant with the protein folding process include transcription, translation, post-translational modifications, degradation through the ubiquitin-proteasome system, and autophagy. As such, the folding process can go awry in several different ways. The pathogenic basis behind most neurodegenerative diseases is that the disruption of protein homeostasis (i.e. proteostasis) at any level will eventually lead to protein misfolding. Misfolded proteins often aggregate and accumulate to trigger neurotoxicity through cellular stress pathways and consequently cause neurodegenerative diseases. The manifestation of a disease is usually dependent on the specific brain region that the neurotoxicity affects. Neurodegenerative diseases are age-associated, and their incidence is expected to rise as humans continue to live longer and pursue a greater life expectancy. We presently review the sequelae of protein misfolding and aggregation, as well as the role of these phenomena in several neurodegenerative diseases including Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, transmissible spongiform encephalopathies, and spinocerebellar ataxia. Strategies for treatment and therapy are also conferred with respect to impairing, inhibiting, or reversing protein misfolding.

Keywords: amyloidogenesis; cell proteostasis network; mitochondrial dysfunction; neurodegenerative disease; protein aggregation; protein misfolding.

PubMed Disclaimer

References

    1. Alzheimer’s, A. (2015). 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 11, 332–384.
    1. Andersen, J.K. (2004). Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10 (Suppl), S18–S25.
    1. Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008). Adapting proteostasis for disease intervention. Science 319, 916–919.
    1. Baranczak, A. and Kelly, J.W. (2016). A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Curr. Opin. Chem. Biol. 32, 10–21.
    1. Barral, J.M., Broadley, S.A., Schaffar, G., and Hartl, F.U. (2004). Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 15, 17–29.

MeSH terms

Substances

LinkOut - more resources